PMID- 36499426
OWN - NLM
STAT- MEDLINE
DCOM- 20221230
LR  - 20221230
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 23
DP  - 2022 Dec 1
TI  - Dihydromyricetin Inhibited Migration and Invasion by Reducing S100A4 Expression 
      through ERK1/2/beta-Catenin Pathway in Human Cervical Cancer Cell Lines.
LID - 10.3390/ijms232315106 [doi]
LID - 15106
AB  - Cervical cancer has a poor prognosis and is the fourth most common cancer among 
      women. Dihydromyricetin (DHM), a flavonoid compound, exhibits several 
      pharmacological activities, including anticancer effects; however, the effects of 
      DHM on cervical cancer have received insufficient research attention. This study 
      examined the antitumor activity and underlying mechanisms of DHM on human 
      cervical cancer. Our results indicated that DHM inhibits migration and invasion 
      in HeLa and SiHa cell lines. Mechanistically, RNA sequencing analysis revealed 
      that DHM suppressed S100A4 mRNA expression in HeLa cells. Moreover, DHM inhibited 
      the protein expressions of beta-catenin and GSK3beta through the regulated 
      extracellular-signal-regulated kinase (ERK)1/2 signaling pathway. By using the 
      ERK1/2 activator, T-BHQ, reverted beta-catenin and S100A4 protein expression and 
      cell migration, which were reduced in response to DHM. In conclusion, our study 
      indicated that DHM inhibited cell migration by reducing the S100A4 expression 
      through the ERK1/2/beta-catenin pathway in human cervical cancer cell lines.
FAU - Hsin, Min-Chieh
AU  - Hsin MC
AD  - Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
AD  - National Institute of Cancer Research, National Health Research Institutes, 
      Zhunan 350, Taiwan.
FAU - Hsiao, Yi-Hsuan
AU  - Hsiao YH
AD  - Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua 
      500, Taiwan.
AD  - Women's Health Research Laboratory, Changhua Christian Hospital, Changhua 500, 
      Taiwan.
AD  - School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
FAU - Chen, Pei-Ni
AU  - Chen PN
AD  - Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
AD  - Department of Medical Research, Chung Shan Medical University Hospital, Taichung 
      402, Taiwan.
FAU - Lin, Chiao-Wen
AU  - Lin CW
AD  - Institute of Oral Sciences, Chung Shan Medical University, Taichung 402, Taiwan.
AD  - Department of Dentistry, Chung Shan Medical University Hospital, Taichung 402, 
      Taiwan.
FAU - Wang, Po-Hui
AU  - Wang PH
AD  - Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
AD  - Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, 
      Taichung 402, Taiwan.
FAU - Yang, Shun-Fa
AU  - Yang SF
AUID- ORCID: 0000-0002-0365-7927
AD  - Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
AD  - Department of Medical Research, Chung Shan Medical University Hospital, Taichung 
      402, Taiwan.
FAU - Lee, Chung-Yuan
AU  - Lee CY
AD  - Department of Obstetrics and Gynecology, Chiayi Chang Gung Memorial Hospital, 
      Chiayi 613, Taiwan.
AD  - Department of Nursing, Chang Gung University of Science and Technology, Chiayi 
      Campus, Chiayi 613, Taiwan.
LA  - eng
GR  - CSH-2022-E-002-Y3/Chung Shan Medical University Hospital/
PT  - Journal Article
DEP - 20221201
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (beta Catenin)
RN  - 0 (S100 Calcium-Binding Protein A4)
RN  - 142662-27-9 (S100A4 protein, human)
RN  - KD8QND6427 (dihydromyricetin)
RN  - 0 (Flavonols)
SB  - IM
MH  - Female
MH  - Humans
MH  - *beta Catenin/metabolism
MH  - Cell Movement
MH  - HeLa Cells
MH  - MAP Kinase Signaling System
MH  - *S100 Calcium-Binding Protein A4/genetics/metabolism
MH  - *Uterine Cervical Neoplasms/drug therapy/genetics
MH  - *Flavonols/pharmacology
PMC - PMC9735508
OTO - NOTNLM
OT  - DHM
OT  - S100A4
OT  - cervical cancer
OT  - metastasis
OT  - beta-catenin
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/12 06:00
MHDA- 2022/12/15 06:00
PMCR- 2022/12/01
CRDT- 2022/12/11 01:20
PHST- 2022/10/31 00:00 [received]
PHST- 2022/11/25 00:00 [revised]
PHST- 2022/11/27 00:00 [accepted]
PHST- 2022/12/11 01:20 [entrez]
PHST- 2022/12/12 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - ijms232315106 [pii]
AID - ijms-23-15106 [pii]
AID - 10.3390/ijms232315106 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Dec 1;23(23):15106. doi: 10.3390/ijms232315106.